In a remarkable evolution, Diabeta, the trusted chatbot of diabetologists, is now expanding its access to pharmacists as well! This expansion is great news for pharmaceutical professionals, providing them with an essential source of up-to-date and comprehensive information.
With data processed from authoritative sources such as SmPCs, guidelines and therapeutic protocols, Diabeta is ready to answer pharmacists’ questions and needs. This significant step marks a new stage in interdisciplinary healthcare collaboration, bringing considerable benefits to patients and professionals involved in their care.
One of the key aspects of this expansion is Diabeta’s ability to provide detailed information about interactions, contraindications, side effects, dosage, and pharmaceutical and pharmacokinetic properties. This comprehensive range of information reinforces the chatbot’s role not only as a healthcare tool, but also as a valuable resource for pharmacy professionals in making informed decisions and providing optimal patient care.
In an age where access to information is crucial to providing quality healthcare, Diabeta is a shining example of innovation and progress. Through its openness to pharmacists, this chatbot demonstrates its commitment to continuously improving the quality of medical and pharmaceutical services, contributing to closer and more efficient collaboration between different branches of the health system.
Integrating Diabetainto the arsenal of pharmacists brings with it multiple benefits, from increased efficiency in decision-making to improving the quality of medical and pharmaceutical care. This initiative is an important step towards building a more interconnected, informed and patient-centred healthcare system.
Diabeta is not just a chatbot, it is an essential tool for diabetologists. Through quick access to quality information from official sources, the platform eliminates uncertainty about available treatments. The natural interaction, supported by voice functions, not only improves communication, but also strengthens doctors’ confidence in the information provided by Diabeta.
Developed by the Romanian company Apollo Technologies, DIABETA benefits from the support of prestigious partners such as Novo Nordisk, Boehringer Ingelheim and Medtronic. This partnership shows how a local initiative can have a global impact, bringing together resources and experiences to tackle diabetes challenges.
